BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 22952954)

  • 1. The proliferation index of specific bone marrow cell compartments from myelodysplastic syndromes is associated with the diagnostic and patient outcome.
    Matarraz S; Teodosio C; Fernandez C; Albors M; Jara-Acevedo M; López A; Gonzalez-Gonzalez M; Gutierrez ML; Flores-Montero J; Cerveró C; Pizarro-Perea M; Paz Garrastazul M; Caballero G; Gutierrez O; Mendez GD; González-Silva M; Laranjeira P; Orfao A
    PLoS One; 2012; 7(8):e44321. PubMed ID: 22952954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cytogenetic characteristics of hematopoietic and stromal progenitor cells in myelodysplastic syndrome].
    Pimenova MA; Parovichnikova EN; Kokhno AV; Domracheva EV; Manakova TE; Mal'tseva IuS; Konnova ML; Shishigina LA; Savchenko VG
    Ter Arkh; 2013; 85(7):34-42. PubMed ID: 24137945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Study on the Characteristics of cell cycle and proliferation of CD34+ hematopoietic stem cells in myelodysplastic syndromes].
    Shi J; Shao ZH; Liu H; Jia HR; Sun J; Bai J; Wu YH; Jing LP; He GS; Cao YR; Wang XL; Tu MF; Hao YS; Yang TY
    Zhonghua Xue Ye Xue Za Zhi; 2004 Nov; 25(11):641-4. PubMed ID: 15634564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone marrow cells from myelodysplastic syndromes show altered immunophenotypic profiles that may contribute to the diagnosis and prognostic stratification of the disease: a pilot study on a series of 56 patients.
    Matarraz S; López A; Barrena S; Fernandez C; Jensen E; Flores-Montero J; Rasillo A; Sayagues JM; Sánchez ML; Bárcena P; Hernandez-Rivas JM; Salvador C; Fernandez-Mosteirín N; Giralt M; Perdiguer L; Laranjeira P; Paiva A; Orfao A
    Cytometry B Clin Cytom; 2010 May; 78(3):154-68. PubMed ID: 20198685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of CDKN1C in the bone marrow of patients with myelodysplastic syndrome and secondary acute myeloid leukemia is associated with poor survival after conventional chemotherapy.
    Radujkovic A; Dietrich S; Andrulis M; Benner A; Longerich T; Pellagatti A; Nanda K; Giese T; Germing U; Baldus S; Boultwood J; Ho AD; Dreger P; Luft T
    Int J Cancer; 2016 Sep; 139(6):1402-13. PubMed ID: 27170453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased immature hematopoietic progenitor cells CD34+/CD38dim in myelodysplasia.
    Monreal MB; Pardo ML; Pavlovsky MA; Fernandez I; Corrado CS; Giere I; Sapia S; Pavlovsky S
    Cytometry B Clin Cytom; 2006 Mar; 70(2):63-70. PubMed ID: 16470534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell-cycle distribution of different cell compartments in normal versus reactive bone marrow: a frame of reference for the study of dysplastic hematopoiesis.
    Matarraz S; Fernandez C; Albors M; Teodosio C; López A; Jara-Acevedo M; Cervero C; Caballero G; Gutierrez O; Orfao A
    Cytometry B Clin Cytom; 2011 Nov; 80(6):354-61. PubMed ID: 21638773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CXCL12+ stromal cells as bone marrow niche for CD34+ hematopoietic cells and their association with disease progression in myelodysplastic syndromes.
    Abe-Suzuki S; Kurata M; Abe S; Onishi I; Kirimura S; Nashimoto M; Murayama T; Hidaka M; Kitagawa M
    Lab Invest; 2014 Nov; 94(11):1212-23. PubMed ID: 25199050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of CD34(-) and CD34(+) cell apoptosis and proliferation in bone marrow of patients with MDS and their impact on survival.
    Xia B; Guo Q; Zhao DD; Zhao HF; Han XP; Wang H; Wu XX; Zhang YZ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1392-7. PubMed ID: 23257440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes.
    Bouscary D; De Vos J; Guesnu M; Jondeau K; Viguier F; Melle J; Picard F; Dreyfus F; Fontenay-Roupie M
    Leukemia; 1997 Jun; 11(6):839-45. PubMed ID: 9177438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD34+ cells from acute myeloid leukemia, myelodysplastic syndromes, and normal bone marrow display different apoptosis and drug resistance-associated phenotypes.
    Suárez L; Vidriales MB; García-Laraña J; Sanz G; Moreno MJ; López A; Barrena S; Martínez R; Tormo M; Palomera L; Lavilla E; López-Berges MC; de Santiago M; de Equiza ME; Miguel JF; Orfao A
    Clin Cancer Res; 2004 Nov; 10(22):7599-606. PubMed ID: 15569991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells.
    Rajapaksa R; Ginzton N; Rott LS; Greenberg PL
    Blood; 1996 Dec; 88(11):4275-87. PubMed ID: 8943864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The immunophenotype of different immature, myeloid and B-cell lineage-committed CD34+ hematopoietic cells allows discrimination between normal/reactive and myelodysplastic syndrome precursors.
    Matarraz S; López A; Barrena S; Fernandez C; Jensen E; Flores J; Bárcena P; Rasillo A; Sayagues JM; Sánchez ML; Hernandez-Campo P; Hernandez Rivas JM; Salvador C; Fernandez-Mosteirín N; Giralt M; Perdiguer L; Orfao A
    Leukemia; 2008 Jun; 22(6):1175-83. PubMed ID: 18337765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased CD34+CD38 -CD123 + cells in myelodysplastic syndrome displaying malignant features similar to those in AML.
    Li LJ; Tao JL; Fu R; Wang HQ; Jiang HJ; Yue LZ; Zhang W; Liu H; Shao ZH
    Int J Hematol; 2014 Jul; 100(1):60-9. PubMed ID: 24846193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of myeloid and lymphoid markers on the surface and in the cytoplasm of mononuclear bone marrow cells in patients with myelodysplastic syndrome.
    Schlesinger M; Silverman LR; Jiang JD; Yagi MJ; Holland JF; Bekesi JG
    J Clin Lab Immunol; 1996; 48(4):149-66. PubMed ID: 9819667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MDS and AML show elevated fractions of CD34-positive blast cell populations with a high anti-apoptotic versus proliferation ratio.
    Mestrum SGC; Roanalis BYV; de Wit NCJ; Drent RJM; Boonen BT; van Hemert WLW; Hopman AHN; Ramaekers FCS; Leers MPG
    Leuk Res; 2024 Jul; 142():107520. PubMed ID: 38776565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic criteria for hypocellular acute leukemia: a clinical entity distinct from overt acute leukemia and myelodysplastic syndrome.
    Nagai K; Kohno T; Chen YX; Tsushima H; Mori H; Nakamura H; Jinnai I; Matsuo T; Kuriyama K; Tomonaga M; Bennett JM
    Leuk Res; 1996 Jul; 20(7):563-74. PubMed ID: 8795690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving the differential diagnosis between myelodysplastic syndromes and reactive peripheral cytopenias by multiparametric flow cytometry: the role of B-cell precursors.
    Reis-Alves SC; Traina F; Metze K; Lorand-Metze I
    Diagn Pathol; 2015 Apr; 10():44. PubMed ID: 25924846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival.
    Corradi G; Baldazzi C; Očadlíková D; Marconi G; Parisi S; Testoni N; Finelli C; Cavo M; Curti A; Ciciarello M
    Stem Cell Res Ther; 2018 Oct; 9(1):271. PubMed ID: 30359303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS.
    Parker JE; Mufti GJ; Rasool F; Mijovic A; Devereux S; Pagliuca A
    Blood; 2000 Dec; 96(12):3932-8. PubMed ID: 11090080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.